Insider Transactions in Q1 2022 at Revance Therapeutics, Inc. (RVNC)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2022
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,835
-1.85%
|
$27,525
$15.79 P/Share
|
|
Mar 15
2022
|
Tobin Schilke CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,607
-4.0%
|
$39,105
$15.79 P/Share
|
|
Mar 15
2022
|
Aubrey Rankin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,372
-1.44%
|
$20,580
$15.79 P/Share
|
|
Mar 15
2022
|
Dwight Moxie CLO & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
5,110
-5.49%
|
$76,650
$15.79 P/Share
|
|
Mar 15
2022
|
Mark J Foley CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,304
-0.43%
|
$49,560
$15.79 P/Share
|
|
Mar 15
2022
|
Abhay Joshi COO, President of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,607
-2.11%
|
$39,105
$15.79 P/Share
|
|
Feb 15
2022
|
Tobin Schilke CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,924
-2.17%
|
$38,012
$13.35 P/Share
|
|
Feb 15
2022
|
Abhay Joshi COO, President of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
5,053
-1.99%
|
$65,689
$13.35 P/Share
|
|
Feb 15
2022
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,429
-1.2%
|
$31,577
$13.35 P/Share
|
|
Feb 02
2022
|
Dwight Moxie CLO & GC |
BUY
Grant, award, or other acquisition
|
Direct |
42,349
+31.86%
|
-
|
|
Feb 02
2022
|
Dustin S Sjuts President |
BUY
Grant, award, or other acquisition
|
Direct |
52,395
+23.21%
|
-
|
|
Feb 02
2022
|
Mark J Foley CEO |
BUY
Grant, award, or other acquisition
|
Direct |
175,649
+15.02%
|
-
|
|
Feb 02
2022
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
42,349
+28.66%
|
-
|